10-QPeriod: Q2 FY2026

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2026

Filed July 30, 2026For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported strong financial performance for the second quarter and first half of 2026, demonstrating significant revenue and profit growth. The company's continuous glucose monitoring (CGM) systems continue to drive this expansion, with notable increases in customer base and revenue per customer. Management highlighted improved manufacturing efficiencies and favorable product mix as contributing factors to expanding gross margins. Financially, Dexcom maintained a robust liquidity position, with substantial cash, cash equivalents, and marketable securities. The company also initiated a significant share repurchase program in the second quarter of 2026, signaling confidence in its financial health and commitment to returning value to shareholders. While facing ongoing litigation, the company asserts it is defending vigorously and does not believe any currently pending proceedings will have a material adverse effect on its business.

Key Highlights

  • 1Revenue increased by 13% to $1.31 billion for Q2 2026 and by 14% to $2.50 billion for the first six months of 2026, driven by increased sales volume and favorable revenue per customer.
  • 2Gross profit grew by 20% to $830.0 million in Q2 2026 and by 24% to $1.58 billion in the first six months, with gross margin improving to 63.4% from 59.5% in the prior year's quarter.
  • 3Operating income saw a substantial increase of 50% to $318.3 million in Q2 2026 and 66% to $573.6 million in the first six months, indicating strong operational leverage.
  • 4Net income rose by 39% to $249.1 million in Q2 2026 and by 57% to $448.6 million in the first six months, with diluted EPS increasing to $0.64 and $1.15, respectively.
  • 5The company ended Q2 2026 with $1.95 billion in cash, cash equivalents, and short-term marketable securities, maintaining a strong liquidity position.
  • 6A new $1.00 billion share repurchase program was authorized in May 2026, under which $600.0 million was repurchased in the first six months of 2026.
  • 7The company reported ongoing litigation, including securities class actions and product-related class actions, and stated its intention to defend vigorously.

Frequently Asked Questions

Dexcom's revenue growth was primarily driven by an increase in sales volume of its disposable sensors, fueled by the continued expansion of its worldwide customer base. Favorable revenue per customer, attributed to changes in payor mix and utilization, also contributed positively. These increases were partially offset by factors like channel and product mix, and rebate eligibility.

The improvement in gross profit and gross margin percentage was due to increased sales volume, benefits from the G7 15 Day product, enhanced manufacturing efficiencies, higher production volumes, and a more favorable manufacturing mix. These factors led to better absorption of fixed costs and were supported by additional quality testing and material validation efforts. However, these gains were partially offset by higher excess and obsolete inventory charges related to the discontinuation of G6 manufacturing.

Dexcom maintains a strong liquidity position with $1.95 billion in cash, cash equivalents, and short-term marketable securities as of June 30, 2026. The company generates positive cash flow from operations and has access to a $200 million revolving credit facility. Additionally, Dexcom has initiated a substantial $1.00 billion share repurchase program, indicating confidence in its financial stability and a commitment to shareholder returns.

Dexcom is currently involved in several legal proceedings, including securities class action lawsuits and class action litigation related to its G6 and G7 devices. The company states that it is defending these claims vigorously and, based on current information, does not believe any of these proceedings will have a material adverse effect on its business, financial condition, or results of operations. However, the outcome of litigation is inherently uncertain.